Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dermatitis Eczema Clear all
Enrolling by invitation No phase listed Observational

Investigation of Filaggrin Gene Mutations Among Latinx Patients With Atopic Dermatitis

NCT06464133
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

NCT00690833
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
topical desonide hydrogel 0.05%
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 4 Interventional

Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis

NCT02732314
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
Investigational OTC Cream, Cosmetic Eczema Cream, 0.05% Desonide Cream, Placebo Cream
Drug · Other
Lead sponsor
Procter & Gamble Beauty
Industry
Eligibility
12 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Jun 27, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07011706
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions
ATI-045, Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

NCT07172321
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jun 27, 2026, 2:52 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of Treatments on Atopic Dermatitis

NCT01631617
View directory record Official record
Conditions
Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic, Skin Diseases
Interventions
Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline, Sodium hypochlorite, Placebo capsules, Placebo Sodium hypochlorite
Drug · Other
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 50 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Not applicable Interventional

Group Eczema Education Visits:Impact on Patient and Family Quality of Life

NCT01143012
View directory record Official record
Conditions
Eczema
Interventions
Group eczema education session, Control group
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Months to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis

NCT00890968
View directory record Official record
Conditions
Hand Dermatoses
Interventions
Triamcinolone Acetonide (TAC) DuraPeel, Placebo DuraPeel
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
San Diego, California • Clinton Township, Michigan • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Jun 27, 2026, 2:52 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03817190
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Placebo
Drug
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Huntington Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

NCT02595008
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
DSXS
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Jun 27, 2026, 2:52 PM EDT
Terminated Phase 1 Interventional Results available

Targeted Investigation of Microbiome Elimination

NCT05177328
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S. hominis A 9 Product, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jun 27, 2026, 2:52 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

NCT01577628
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Asthma, Food Allergies, Allergic Rhinitis
Interventions
Lipikar Balm AP
Drug
Lead sponsor
Cosmetique Active International
Industry
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Canton, Michigan • Fort Gratiot, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Jun 27, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional

Seal, Stopping Eczema and Allergy Study

NCT03742414
View directory record Official record
Conditions
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Combination Product · Other
Lead sponsor
Kari Nadeau, MD, PhD
Other
Eligibility
1 Week to 12 Weeks
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 27, 2026, 2:52 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT00605878
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin

NCT02120833
View directory record Official record
Conditions
Eczema
Interventions
EpiCeram® Skin Barrier Emulsion, Colloidal Oatmeal Cream
Device · Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Months to 35 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jun 27, 2026, 2:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)

NCT05583019
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Healthy
Interventions
GENEActiv Accelerometry Device, Centrepoint Insights Watch (CPIW) Accelerometry Device, Apple Watch Accelerometry Device, Polysomnography, Videography
Device
Lead sponsor
SymmetryScience Group, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

NCT03645057
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole, Tacrolimus 0.03% Ointment
Drug
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 15 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 4 Interventional

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

NCT00121381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

NCT03139981
View directory record Official record
Conditions
Dermatitis, Atopic, Dermatitis Eczema, Dermatitis, Eczematous
Interventions
ASN002, Placebo Oral Tablet
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
9
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jun 27, 2026, 2:52 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

NCT03540160
View directory record Official record
Conditions
Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions
5 mg Serlopitant Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Jun 27, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
APG777, Placebo
Drug
Lead sponsor
Apogee Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

Efalizumab for Eczema

NCT00146003
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Efalizumab treatment
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Jun 27, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

NCT03725722
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • Encino, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Jun 27, 2026, 2:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus

NCT00407069
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Jun 27, 2026, 2:52 PM EDT